Alkermes plc ALKS
As ofNov 20, 2026, 11:27 AM EST
- YTD
- +64.28%
- 1 year
- +63.05%
5D -0.29 (-0.62%)
- Market cap
- 7.72B
- Revenue (ttm)
- 1.75B
- Profit margin
- -0.02%
- EPS (ttm)
- -0.01
- Shares out
- 168.04M
- Forward P/E
- 34.15
- YTD return
- +64.28%
- 1-year return
- +63.05%
- 50-day average
- 43.71
- 200-day average
- 41.30
- Volume
- 218.93K
- Avg volume
- 1.89M
- Open
- 45.79
- Previous close
- 46.18
- Day's range
- 45.79 – 46.89
- 52-week range
- 27.00 – 55.67
- Beta
- 0.23
- Analysts
- Buy
- Price target
- 57.74 (+25.6%)
- Earnings date
- Feb 24, 2027
Key statistics
- Enterprise value
- 8.69B
- PEG ratio
- 1.96
- Price / sales
- 4.43
- Price / book
- 4.16
- Revenue growth
- 21.80%
- Free cash flow
- 230.84M
- Total cash
- 755.46M
- Total debt
- 1.57B
- Return on equity
- -0.02%
- Short % of float
- 16.19%
Fundamental scorecard
4 of 25 checks passed on ALKS’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 38.00
- Target (mean)
- 57.74
- Target (high)
- 83.00
- Strong buy3
- Buy12
- Hold4
- Sell0
- Strong sell1
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.00354.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.24 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.08175 | 0.09 | +0.17 | +210.09% |
| Jul 28, 2026 | Jun 30, 2026 | -0.02745 | 0.70 | +0.73 | +2,650.09% |
| May 5, 2026 | Mar 31, 2026 | -0.57 | -0.40 | +0.17 | +29.82% |
| Feb 25, 2026 | Dec 31, 2025 | 0.43 | 0.34 | -0.09 | -20.93% |
| Oct 28, 2025 | Sep 30, 2025 | 0.3688 | 0.49 | +0.12 | +32.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 4, 2026 | Wells Fargo | main | Overweight | Overweight |
| Nov 4, 2026 | HC Wainwright & Co. | main | Neutral | Neutral |
| Sep 22, 2026 | RBC Capital | reit | Outperform | Outperform |
| Sep 22, 2026 | Baird | main | Outperform | Outperform |
| Sep 21, 2026 | Needham | reit | Buy | Buy |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- Website
- alkermes.com
News
Bessemer Group Inc. Acquires 202,616 Shares of Alkermes plc $ALKS
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68
HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50
Alkermes Q3 2026 Earnings Call Transcript Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate
Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on ALKS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN IAIN MICHAEL | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 25, 2025 | 148,196 |
| COOKE SHANE M | Director | Conversion of Exercise of derivative security | May 20, 2026 | 106,679 |
| GAFFIN DAVID JOSEPH | Officer | Sale | Nov 2, 2026 | 219,353 |
| HOPKINSON CRAIG C | Officer | Sale | Aug 31, 2026 | 65,389 |
| JACKSON BLAIR CURTIS | Chief Operating Officer | Conversion of Exercise of derivative security | Feb 25, 2026 | 241,308 |
| MCKEON BRIAN P | Director | Conversion of Exercise of derivative security | May 20, 2026 | 48,536 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.08% | 28,703,354 | 1.33B | Sep 29, 2026 |
| State Street Corporation | 6.03% | 10,131,249 | 468.06M | Sep 29, 2026 |
| Baker Bros. Advisors, LP | 5.96% | 10,012,267 | 462.57M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.63% | 9,459,289 | 437.02M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 7,503,336 | 346.65M | Sep 29, 2026 |
| Renaissance Technologies, LLC | 3.86% | 6,493,828 | 300.01M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 9,993,409 | 461.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 5,297,487 | 244.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 4,340,866 | 200.55M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,823,805 | 176.66M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.94% | 3,254,864 | 150.37M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 2,202,262 | 101.74M | Jun 29, 2026 |
